A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice

Arab, Atefeh; Behravan, Javad; Razazan, Atefeh; Gholizadeh, Zahra; Nikpoor, Amin Reza; Barati, Nastaran; Mosaffa, Fatemeh; Badiee, Ali; Jaafari, Mahmoud Reza

doi:10.1080/1061186x.2017.1387788

Cited by 41 publications

(20 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, PEGylation of liposomes (decoration of the liposome surface with polyethylene glycol, PEG) prevents their binding with serum proteins and reduces their uptake by reticuloendothelial system (RES) [67]. The protective effect of PEG depends on its molecular weight [61,64,68]. However, PEGylation has unwanted side effects (such as decrease of the affinity of liposomes to a cell membrane and hindered drug release in cytosol) that should be also taken into account [61].…”

Section: Liposome-encapsulated Proteins and Peptidesmentioning

confidence: 99%

Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins

2019

View full text Add to dashboard Cite

Supramolecular chemistry holds great potential for the design of versatile and safe carriers for therapeutic proteins and peptides. Nanocarriers can be designed to meet specific criteria for given application (exact drug, administration route, target tissue, etc.). However, alterations in the topology of formulation components can drastically change their activity. This is why the supramolecular topology of therapeutic nanoconstructions has to be considered. Herein, we discuss several topological groups used for the design of nanoformulations for peptide and protein delivery: modification of polypeptide chains by host-guest interactions; packaging of proteins and peptides into liposomes; complexation and conjugation with dendrimers. Each topological type has its own advantages and disadvantages, so careful design of nanoformulations is needed. Ideally, each case where nanomedicine is needed requires a therapeutic construction specially created for that taking into account features of the administration route, target tissue, or organ, properties of a drug, its bioavailability, etc. The wide number of studies in the field of protein delivery by supramolecular and nanocarriers for proteins and peptides evidence their increasing potential for different aspects of the innovative medicine. Although significant progress has been achieved in the field, there are several remaining challenges to be overcome in future.

show abstract

Section: Liposome-encapsulated Proteins and Peptidesmentioning

confidence: 99%

Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins

2019

View full text Add to dashboard Cite

show abstract

“…Liposomal formulations were used both as delivery vehicles and as immune adjuvants for enhancement of the stimulation of immune response against established rHER2/ neu protein overexpressing tumors in BALB/c mice. The liposomal formulation of E75 peptide was able to evoke specific CD8 + CTLs response that protected mice against HER2 tumor challenge in both therapeutic and prophylactic experiments (Arab et al 2018a). Moreover, and in a similar line of research, we formulated the GP2 peptide in liposomal carriers consisting of dimyristoylphosphatidylcoline, dimyristoylphosphoglycerol, DOPE, cholesterol and monophosphoryl lipid A (as an adjuvant).…”

Section: Strategies To Improve Immunogenicity Of Peptide Vaccinesmentioning

confidence: 98%

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

Arab

Yazdian‐Robati

Behravan

2020

Arch. Immunol. Ther. Exp.

Self Cite

View full text Add to dashboard Cite

Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically improved by understanding of the immune regulatory mechanisms of tumor microenvironment. Passive immunotherapy utilizing recombinant monoclonal antibodies (mAbs), particularly trastuzumab and pertuzumab has proved to be an effective strategy in HER2-positive breast cancer treatment. However, resistance to mAb therapy and relapse of disease are still considered important challenges in clinical practice. There are increasing reports on the induction of cellular and humoral immune responses in HER2-positive breast cancer patients. More recently, increasing efforts are focused on using HER2-derived peptide vaccines for active immunotherapy. Here, we discuss the development of various HER2-derived vaccines tested in animal models and human clinical trials. Different formulations and strategies to improve immunogenicity of the antigens in animal studies are also discussed. Furthermore, other immunotherapeutic approaches to HER2 breast cancer including, CTLA-4 inhibitors, immune checkpoint inhibitors, anti PD-1/PD-L1 antibodies are presented.

show abstract

“…A recently published study created and tested a liposomal formulation of the vaccine by attaching the E75 peptide to the surface of distearoyl phosphocholine and distearoyl phophoglycerol of nano-liposomes for vaccination. 25 ELISpot analysis and flow cytometry demonstrated significantly enhanced antitumor responses as well as tumor inhibition and prolonged survival time in the mouse TUBO model, which is a cell line that overexpresses the rHER/neu protein. Thus, this approach offers promise for translation to human clinical trials.…”

Section: Other E75 Studies In Breast Cancermentioning

confidence: 99%

<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>

Dillon¹,

Brenin²,

Slingluff³

2020

BCTT

View full text Add to dashboard Cite

Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.

show abstract

A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice

Cited by 41 publications

References 45 publications

Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins

Topological Aspects of the Design of Nanocarriers for Therapeutic Peptides and Proteins

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>

Contact Info

Product

Resources

About